amgen glp-1 obesity drug market potential Four Strategies for Competing in the Crowded Marketplace Amgen's weight-loss drug fails to

From persistent gastrointestinal symptoms to aspiration risk and functional obstruction, these drugs are changing what walks through the ED doors

These drugs mimic the action of the glucagon-like peptide-1 (GLP-1), a hormone that stimulates insulin secretion in response to meals

Systemic inflammation associated with obesity and diabetes leads to inefficient muscle function, sarcopenia, 6 , 7 and fatty or fibrous infiltrations of the muscle 7 which reduce strength and contractile function of muscles

Its therapeutic potential, as extensively reviewed by Nauck et al

Youre talking $6,000 a year, and that is still probably more than insurers are paying right now with discounts, said Dr